گروه دارویی سبحان
دسبحا | Stocks - Tehran Stock Exchange (TSE)
داروهای شیمیایی و گیاهی
Sector:
داروهای شیمیایی و گیاهی
Market Type:
Stocks
Status:
Authorized
Last Price: 8,310 1.19
Close Price: 8,450
Income Statement
AGM
Interim
2026/06/22 Fiscal Year 2026/03/2012 Month | 2025/05/26 Fiscal Year 2025/03/2012 Month | 2024/06/20 Fiscal Year 2024/03/1912 Month | ||
|---|---|---|---|---|
Revenue from Services & Sales | - | 1.389 Trillion | 5.843 Trillion | |
Total Revenues | 2.674 Trillion | 1.389 Trillion | 5.843 Trillion | |
Gross Profit | 2.674 Trillion | 1.389 Trillion | 5.843 Trillion | |
General & Administrative Expenses | 115.536 Billion | 187.186 Billion | 150.506 Billion | |
Operating Profit (Loss) | 2.321 Trillion | 1.202 Trillion | 5.693 Trillion | |
Profit Before Tax | 2.953 Trillion | 3.451 Trillion | 7.386 Trillion | |
Net Profit (Loss) After Tax | 2.953 Trillion | 3.451 Trillion | 7.386 Trillion | |
Retained Earnings at Beginning of Period | 3.554 Trillion | 6.906 Trillion | 5.88 Trillion | |
Approved Dividends — Prior Year AGM | -558 Billion | -4.255 Trillion | -4.255 Trillion | |
Transfer from Other Equity Items | -62.348 Billion | - | - | |
Allocable Profit | 5.887 Trillion | 6.103 Trillion | 9.011 Trillion | |
Legal Reserve | 147.648 Billion | - | 53.624 Billion | |
Other Reserves | 958.533 Billion | 2.548 Trillion | 2.052 Trillion | |
Approved Dividends — Current Year | 493.714 Billion | 558 Billion | 4.255 Trillion | |
Retained Earnings at End of Period | 4.287 Trillion | 2.996 Trillion | 2.651 Trillion | |
هزینه استهلاک | 1.822 Billion | - | - | |
سایر هزینه ها | 235.59 Billion | - | - | |
درآمد سود سهام | 2.674 Trillion | - | - |